Our management team has demonstrable expertise in developing and commercialising diagnostics, building and protecting patent portfolios, and scaling successful businesses.

Meet the management team

Dr Mark Street-Docherty, CEO

Mark is a seasoned, scientifically-focused IVD commercial professional with extensive experience in bringing innovative products to the global marketplace. He joined MicrosensDx in 2020, having previously spent a number of years as CEO leading the award-winning VC backed Elucigene Diagnostics business, culminating in its successful sale and merger to the Yourgene Health Group Plc in 2019.

LinkedIn Profile

Dr Stuart Wilson, CSO

After completing his PhD, Stuart undertook microbiology and virology research, including working on highly infectious viral pathogens; subsequently he worked on developing molecular assays for tuberculosis, malaria and leishmaniasis. As Deputy Director of the National TB Reference Laboratory he set up the national testing service for tuberculosis in the UK, working in what has now become Public Health England.

In 2000 he co-founded MicrosensDx to develop detection methods for the prion disease BSE (‘mad cow’) and the human form vCJD. Stuart has also co-founded 3 other life science companies focusing on sepsis, therapeutics for neurodegenerative diseases and rapid infectious disease testing for blood-borne pathogens.

Andrew Turner, Chairman

With extensive international experience across multiple industries from FMCG to Biotech, Andrew now focuses on change management, strategy and development. With working experience in Europe, Germany, Italy, Belgium and Sweden as well as South Asia, currently Andrew is serving in an advisory capacity to a number of PE and SME companies, supporting start up and small cap companies to develop strategies for growth and success in the Biotech sector, amongst others.

He has been Chairman of the board at MicrosensDx since 2019.

LinkedIn Profile